PRESS RELEASE
Australia's Therapeutic Goods Administration Approves SKY-0515 Clinical Trial
The TGA has approved the clinical trial application for SKY-0515 in Australia, supporting the global FALCON-HD Phase 2/3 trial expansion.
LEARN MORE →News
Latest news, press releases, and clinical updates from Skyhawk Therapeutics.
CLINICAL UPDATE
Nine Month Interim Results from Phase 1 Clinical Trial of SKY-0515
Updated Phase 1 data shows sustained HTT lowering and clinical benefit through nine months of treatment with SKY-0515 in Huntington's Disease patients.
LEARN MORE → PRESS RELEASE
Skyhawk Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany
Skyhawk and Merck KGaA enter a multi-target collaboration to discover and develop RNA-targeted small molecule therapies across multiple therapeutic areas.
LEARN MORE → CLINICAL UPDATE
Skyhawk Reports Positive First Results in Huntington's Patients for Oral Drug SKY-0515
SKY-0515 achieves 62% reduction in mutant HTT protein with meaningful clinical improvements in cUHDRS at 3, 6 and 9 months in the Phase 1 clinical trial.
LEARN MORE →